Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (w/v) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review


  1. Food purchases in households with and without diabetes based on consumer purchase data

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Mutation of KRAS in colorectal adenocarcinoma in Greenland

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Vis graf over relationer

PURPOSE: To examine the physicochemical properties of five preservative-free (PF) 0.005% latanoprost ophthalmic products; Monoprost®, Latanest®, Gaap Ofteno®, Xalmono®, and Xaloptic® Free. Furthermore, the study investigated the mucin production and cell survival of primary cultured human conjunctival goblet cells when treated with PF eye drops.

METHOD: The pH value, osmolality, and surface tension were examined. Cell survival was analyzed using lactate dehydrogenase and tetrazolium dye colorimetric assays. Mucin production was analyzed with immunohistochemical staining.

RESULTS: Monoprost® (pH value 6.84 ± 0.032) had a pH value closest to the pH value of tear fluid (pH value 7.4-7.6), whereas Gaap Ofteno® (pH value 6.34 ± 0.004) and Latanest® (pH value 6.33 ± 0.003) had the lowest pH values. Gaap Ofteno® (325.9 ± 2.9 mosmol/kg) showed iso-osmolar probabilities, whereas the other products were hypo-osmolar. Gaap Ofteno® (60.31 ± 0.35 mN/m) had a higher surface tension compared to the tear fluid (40 to 46 mN/m), as described in the literature. No significant differences in goblet cell survival or mucin release were observed between the treatments and control.

CONCLUSION: Significant differences in pH value, osmolality, and surface tension were observed. However, this did not affect the viability of the goblet cells or the release of mucin. Clinical studies are required to evaluate the long-term effects of use on efficacy and safety.

TidsskriftJournal of Clinical Medicine
Udgave nummer11
StatusUdgivet - 31 maj 2022

ID: 78746421